Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2024 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• Prescrire events
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Semaglutide in secondary cardiovascular prevention in overweight or obese patients  Marketing Authorisations   In a placebo-controlled trial in patients at high risk for cardiovascular events, their incidence was 1.5 percentage points lower in the injectable semaglutide group than in the placebo group, with no reduction in mortality and at a cost of frequent, and often troublesome, adverse effects. Full article available for download by subscribers 1 June 2024

Recurring criticisms of Prescrire: how do we answer?   Outlook   Ever since Prescrire was launched in 1981, it has been criticised for its method of analysis, editorial process and certain editorial choices. This article addresses a few of the recurring criticisms levelled against Prescrire. Full article available for download by subscribers 1 June 2024

Paternal exposure to valproate drugs in the period prior to conception: neurodevelopmental disorders in children?  Adverse Effects   In 2023, epidemiological data suggesting an increased incidence of neurodevelopmental disorders in children whose father had taken a valproate drug during the 3 months prior to conception led several drug regulatory agencies to issue alerts about this potential risk. As of early 2024, what are the main evaluation data concerning this risk, how strong is the evidence they provide, and to what extent should they be taken into account in clinical practice? Full article available for download by subscribers (3 pages) 1 June 2024

The finances of Association Mieux Prescrire: 2023 annual report   Outlook   Association Mieux Prescrire, the legal entity that publishes Prescrire's journals and continuing education programmes, makes its accounts public every year. The summary of its 2023 annual financial report is publicly available here. Full article available for download (free) 1 June 2024

Check before deciding  Editorial  Many people take medicines regularly for months or even years. If their condition worsens or a new health problem develops, other medicines are often added. When prescribing, advising, dispensing or administering an additional drug, it is essential to consider the adverse effects that could result from interactions with the patient's current medications.   Full article available for download (free) 1 May 2024

Tezepelumab (Tezspire°) in severe asthma in adults and adolescents  Marketing Authorisations   Tezepelumab is a monoclonal antibody that binds to the cytokine thymic stromal lymphopoietin. It has been authorised in the European Union for use in adults and adolescents with severe asthma, as an add-on to insufficiently effective maintenance treatment with a high-dose inhaled corticosteroid combined with at least one other drug. In this situation, is tezepelumab more effective than an oral corticosteroid or any of the other monoclonal antibodies authorised in asthma, does it help reduce patients’ oral corticosteroid requirements, and what are its adverse effects? Full article available for download by subscribers (4 pages) 1 May 2024

The Prescrire Drug Awards for 2023 None of the drugs examined by Prescrire in 2023 represented a major therapeutic advance worthy of a Pilule d'Or (Golden Pill Award). Only one drug received an award, earning a place on the Honours List. Full article available for download (free) 1 May 2024

Pregabalin during the first trimester of pregnancy: probably a slight increase in major malformations  Adverse Effects   New pharmacoepidemiological data show a higher incidence of various major congenital malformations following in­-utero exposure to pregabalin than in control groups. What is the evidence for this risk, and what are the consequences in practice? Full article available for download by subscribers (2 pages) 1 May 2024

Efgartigimod alfa (Vyvgart°) in generalised myasthenia gravis  Marketing Authorisations   Efgartigimod alfa, an antibody Fc fragment that is claimed to increase IgG degradation by blocking the neonatal Fc receptor, has been authorised in the European Union as an add-on treatment in adults with generalised myasthenia gravis who have autoantibodies directed against acetylcholine receptors. Is efgartigimod alfa more effective at alleviating the symptoms of the disease than the other treatments proposed in this situation, does it prevent the complications of the disease, including myasthenic crisis, and what are its adverse effects? Full article available for download by subscribers (3 pages) 1 May 2024

European Commission public consultation on the revision of European pharmaceutical legislation: Prescrire's response  Advancing Healthcare Policy   The European Commission has launched a major revision of European pharmaceutical legislation. In November 2023, it opened its proposals to public consultation, to which Prescrire has responded. While Prescrire welcomes several of the proposals, some of them need to be further developed. Others are counterproductive or even dangerous, and should be rejected. Full article (4 pages) available for download (free) 1 May 2024

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

• Sitemap |
• Terms of use |
• Contact
• |Top of page